Equities Analysts Offer Predictions for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – William Blair reduced their Q3 2025 EPS estimates for Becton, Dickinson and Company in a note issued to investors on Monday, July 14th. William Blair analyst A. Brackmann now anticipates that the medical instruments supplier will post earnings of $3.43 per share for the quarter, down from their previous estimate of $3.52. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. William Blair also issued estimates for Becton, Dickinson and Company’s FY2025 earnings at $14.20 EPS and FY2026 earnings at $14.75 EPS.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.17 earnings per share.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a report on Tuesday, June 3rd. Raymond James Financial lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price for the company. in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $219.22.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $178.23 on Wednesday. The firm has a market capitalization of $51.08 billion, a PE ratio of 34.01, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company’s fifty day moving average price is $173.02 and its 200-day moving average price is $205.02.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after purchasing an additional 448,644 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after purchasing an additional 667,957 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Becton, Dickinson and Company by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier’s stock worth $1,437,161,000 after purchasing an additional 66,024 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock worth $1,012,649,000 after purchasing an additional 312,124 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares of the company’s stock, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were given a $1.04 dividend. The ex-dividend date was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.33%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 79.39%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.